INTRODUCTION: Inconsistent evidences of the metabolic syndrome (MetS) impact on vascular reactivity raise questions on flow-mediated dilation (FMD) discriminatory power for disturbances induced by this clustering of risk factors. Previous reports, however, suggest that covariates such as the follow-up of the artery diameter changes, the arterial size and shear stress affect FMD responses and consequently its discriminatory power for distinctive clinical profiles. OBJECTIVE: To determine the impact of MetS on traditional, arterial size- and shear-rate-adjusted FMD, the follow-up-derived time-to-peak diameter (TP), as well as their power for discriminating subjects with this clustering of risk factors from a sample of healthy individuals. METHODS: Twenty-one MetS and ten healthy subjects underwent an assessment of endothelial function via FMD. RESULTS: Traditional and allometrically scaled FMD did not differ between groups (P>0·05) as well as the approach in which the covariate was the peak diameter shear rate. In the existence of MetS, TP was longer (67·7 ± 16·4 s versus healthy 42·1 ± 16·3 s, P = 0·001). ROC curve analysis indicated that TP (AUC = 0·871 [95% CI, 0·718-1·000]) had greater power of discrimination for MetS than FMD approaches. In addition, TP presented a moderate and significant association with sE-selectin (r = 0·458, P = 0·048). CONCLUSION: Time-to-peak diameter (TP) rather than FMD distinguished MetS from a healthy profile. Therefore, at least in subjects with MetS, TP may provide insights into the impact of this clustering of risk factors on the vascular phenotype.
INTRODUCTION: Inconsistent evidences of the metabolic syndrome (MetS) impact on vascular reactivity raise questions on flow-mediated dilation (FMD) discriminatory power for disturbances induced by this clustering of risk factors. Previous reports, however, suggest that covariates such as the follow-up of the artery diameter changes, the arterial size and shear stress affect FMD responses and consequently its discriminatory power for distinctive clinical profiles. OBJECTIVE: To determine the impact of MetS on traditional, arterial size- and shear-rate-adjusted FMD, the follow-up-derived time-to-peak diameter (TP), as well as their power for discriminating subjects with this clustering of risk factors from a sample of healthy individuals. METHODS: Twenty-one MetS and ten healthy subjects underwent an assessment of endothelial function via FMD. RESULTS: Traditional and allometrically scaled FMD did not differ between groups (P>0·05) as well as the approach in which the covariate was the peak diameter shear rate. In the existence of MetS, TP was longer (67·7 ± 16·4 s versus healthy 42·1 ± 16·3 s, P = 0·001). ROC curve analysis indicated that TP (AUC = 0·871 [95% CI, 0·718-1·000]) had greater power of discrimination for MetS than FMD approaches. In addition, TP presented a moderate and significant association with sE-selectin (r = 0·458, P = 0·048). CONCLUSION: Time-to-peak diameter (TP) rather than FMD distinguished MetS from a healthy profile. Therefore, at least in subjects with MetS, TP may provide insights into the impact of this clustering of risk factors on the vascular phenotype.
Authors: Kristen L Nowak; Anna Jovanovich; Heather Farmer-Bailey; Nina Bispham; Taylor Struemph; Mikaela Malaczewski; Wei Wang; Michel Chonchol Journal: Kidney360 Date: 2020-06-25
Authors: Natalia G Rocha; Allan R K Sales; Leticia A Penedo; Felipe S Pereira; Mayra S Silva; Renan L Miranda; Jemima F R Silva; Bruno M Silva; Aline A Santos; Antonio C L Nobrega Journal: Biomed Res Int Date: 2015-10-18 Impact factor: 3.411
Authors: Vinicius Pacheco Garcia; Helena Naly Miguens Rocha; Allan Robson Kluser Sales; Natália Galito Rocha; Antonio Claudio Lucas da Nóbrega Journal: Arq Bras Cardiol Date: 2016-03 Impact factor: 2.000
Authors: Riobaldo M R Cintra; Alexandre A S Soares; Ikaro Breder; Daniel B Munhoz; Joaquim Barreto; Sheila T Kimura-Medorima; Pamela Cavalcante; Renata Zanchetta; Jessica Cunha Breder; Camila Moreira; Vitor W Virginio; Isabella Bonilha; Jose Carlos Lima-Junior; Otavio R Coelho-Filho; Vaneza L W Wolf; Gil Guerra-Junior; Daniela C Oliveira; Rodrigo Haeitmann; Vicente H R Fernandes; Wilson Nadruz; Fernando R P Chaves; Carlos E L Arieta; Thiago Quinaglia; Andrei C Sposito Journal: Diabetol Metab Syndr Date: 2019-07-31 Impact factor: 3.320